{"filing":{"accession_number":"0001437749-26-027672","cik":"0001710340","ticker":"ETON","company_name":"Eton Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"eton20260608_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/eton20260608_8k.htm"},"events":[{"id":27611,"run_id":25176,"accession_number":"0001437749-26-027672","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The press release (Exhibit 99.1) discloses comprehensive financial results including record revenue of $37.6 million (99% YoY growth), net income of $11.6 million ($0.35 per diluted share), and raised full-year 2026 revenue guidance to exceed $145 million. The disclosure is material to investors as it demonstrates strong operational performance and includes forward-looking guidance adjustments.","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29202,"accession_number":"0001437749-26-027672","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The press release (Exhibit 99.1) discloses comprehensive financial results including record revenue of $37.6 million (99% YoY growth), net income of $11.6 million ($0.35 per diluted share), and raised full-year 2026 revenue guidance to exceed $145 million. The disclosure is material to investors as it demonstrates strong operational performance and includes forward-looking guidance adjustments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:03:33.144322+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29202,"accession_number":"0001437749-26-027672","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The press release (Exhibit 99.1) discloses comprehensive financial results including record revenue of $37.6 million (99% YoY growth), net income of $11.6 million ($0.35 per diluted share), and raised full-year 2026 revenue guidance to exceed $145 million. The disclosure is material to investors as it demonstrates strong operational performance and includes forward-looking guidance adjustments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:03:33.144322+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-13"}]}